Details of the Drug

General Information of Drug (ID: DMY3T0L)

Drug Name
DS-1211
Synonyms
N-Acetyl-D-leucine; 19764-30-8; Ac-D-Leu-OH; D-leucine, N-acetyl-; N-Acetyl-R-leucine; (2R)-2-acetamido-4-methylpentanoic acid; Acetylleucine, D-; Acetylleucine, (R)-; (R)-2-acetamido-4-methylpentanoic acid; Leucine, N-acetyl-, D-; acetyl-d-leucine; 91WU82GA22; MFCD00066069; 2,N-Acetyl-D-leucine; D-acetylleucine; UNII-91WU82GA22; (R)-acetylleucine; N-acetyl-D-Leu; NCGC00094935-01; N-acetyl-(D)-leucine; SCHEMBL714003; CHEMBL174357; CHEBI:94479; DTXSID50361310; CHEBI:146296; WXNXCEHXYPACJF-SSDOTTSWSA-N; HY-Y1080; s4514; AKOS016842336; AKOS025117328; CCG-266380; CS-W020713; DS-1211; FD21901; NCGC00094935-02; AC-22376; A0713; AM20090137; A-1455; A20910; EN300-321381; Q-100200; BRD-K05831461-001-01-8; Z851793110
Indication
Disease Entry ICD 11 Status REF
Pseudoxanthoma elasticum EC40 Phase 2 [1]
Drug Type
Small molecule
Structure
3D MOL 2D MOL
Chemical Identifiers
Formula
C8H15NO3
Canonical SMILES
CC(C)CC(C(=O)O)NC(=O)C
InChI
InChI=1S/C8H15NO3/c1-5(2)4-7(8(11)12)9-6(3)10/h5,7H,4H2,1-3H3,(H,9,10)(H,11,12)/t7-/m1/s1
InChIKey
WXNXCEHXYPACJF-SSDOTTSWSA-N
Cross-matching ID
PubChem CID
1241420
UNII
91WU82GA22
DrugBank ID
DB17837
TTD ID
D29GPF
Drug Pharmacogenomic Perturbation (DPP)NEW Click to Jump to the Detailed DPP Information of This Drug
Drug ADMET Endpoint Profile (DAE)NEW Click to Jump to the Detailed DAE Information of This Drug

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Alkaline phosphatase tissue-nonspecific (ALPL) TTMR5UV PPBT_HUMAN Inhibitor [2]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease Pseudoxanthoma elasticum
ICD Disease Classification EC40
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Alkaline phosphatase tissue-nonspecific (ALPL) DTT ALPL 4.67E-13 -0.15 -0.79
Molecular Expression Atlas (MEA) Jump to Detail Molecular Expression Atlas of This Drug

References

1 ClinicalTrials.gov (NCT05569252) A Phase 2, 12-Week, Randomized, Double-Blind, Placebo-Controlled Study of DS-1211b in Individuals With PseudoXanthoma Elasticum. U.S.National Institutes of Health.
2 In Vitro and In Vivo Pharmacological Profiles of DS-1211, a Novel Potent, Selective, and Orally Bioavailable Tissue-Nonspecific Alkaline Phosphatase Inhibitor. J Bone Miner Res. 2022 Oct;37(10):2033-2043.